A rationally designed scorpion toxin-derived peptide (ADIP-6) selectively blocks the Kv1.3 potassium channel at sub-nanomolar potency (IC50 = 0.8 nM) with minimal off-target effects, and effectively suppressed autoimmune responses in both cellular and animal models.
IC50 = 0.8 nM with >1,000× selectivityADIP-6 achieves sub-nanomolar Kv1.3 potency with minimal activity on other channels at 1 μM, combined with in vivo efficacy in autoimmune encephalomyelitis
What the researchers found
Starting from scorpion toxin BmKTX as a template, the researchers engineered ADIP-6 (BmKTX-K6D/D19K/D33K) through strategic acidic residue redistribution:
- Selectivity: IC50 of 0.8 ± 0.1 nM against hKv1.3; minimal inhibition of other potassium channels even at 1 μM (>1,000-fold selectivity)
- Cellular: Significantly suppressed IL-2 production in Jurkat T cells (confirming functional immunosuppression)
- In vivo: Reduced delayed-type hypersensitivity responses and alleviated disease severity in a rat model of experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis
The design strategy — negatively charged residue scanning based on peptide-potassium channel interaction principles — provides a general framework for creating selective channel blockers.
Why it matters
Current immunosuppressants (like cyclosporine) suppress the entire immune system, increasing infection and cancer risk. The Kv1.3 channel is preferentially expressed on the effector memory T cells that drive autoimmune disease, while other T cell types use a different channel (KCa3.1). Selectively blocking Kv1.3 could suppress autoimmune attacks while preserving overall immune defense. ADIP-6's >1,000-fold selectivity over other channels is a major advance toward this goal, and its efficacy in an MS model demonstrates therapeutic potential.
How the study worked
Rational peptide engineering using BmKTX (scorpion toxin) as a template. Acidic residue distribution was modulated based on peptide-potassium channel interaction principles to exploit structural differences between hKv1.3 and other channels. The resulting peptides were synthesized and characterized by electrophysiology for channel selectivity (IC50 determination across multiple potassium channels). Functional immunosuppression was tested by measuring IL-2 production in Jurkat cells. In vivo efficacy was assessed in delayed-type hypersensitivity and rat EAE (experimental autoimmune encephalomyelitis) models.
What this study cannot tell us
Preclinical study — no human safety or efficacy data. The rat EAE model approximates but doesn't fully replicate human multiple sclerosis. Peptide drugs face challenges with stability, oral bioavailability, and potential immunogenicity that weren't addressed. The selectivity panel, while impressive, may not cover all relevant human potassium channels. Long-term safety of chronic Kv1.3 blockade needs assessment. Manufacturing scalability of the engineered peptide at clinical grade wasn't discussed.
How to read the evidence
This is a preclinical drug design study with comprehensive validation: in vitro selectivity profiling, cellular immunosuppression assay, and two in vivo models (DTH and EAE). The multi-level evidence is strong for a preclinical study, but translation to human autoimmune disease therapy requires extensive additional work.
When this study was published
Published in 2026, this is a very recent study representing state-of-the-art rational peptide engineering for ion channel drug targets.
The bigger picture
Venom-derived peptides are one of the richest sources of potent ion channel modulators — millions of years of evolution have optimized them for channel binding. This study demonstrates how rational engineering can transform a non-selective venom toxin into a highly selective drug candidate. The Kv1.3 channel has been a target for decades but achieving selectivity has been the main obstacle. ADIP-6's combination of sub-nanomolar potency and >1,000-fold selectivity represents a significant advance that could revive interest in Kv1.3-targeted immunotherapy.
Questions still open
- Could ADIP-6 be effective in human autoimmune diseases beyond the MS model tested?
- How does chronic Kv1.3 blockade affect overall immune competence and infection susceptibility?
- Can the negatively charged residue scanning strategy be applied to other venom peptide templates to create selective blockers for other ion channels?
Common questions
Why use scorpion venom as a starting point for drug design?
How could blocking a potassium channel treat autoimmune disease?
Read the original research
Peptide‑potassium channel interaction law-guided design of Kv1.3 channel-selective peptide immunosuppressants.
International journal of biological macromolecules, 341(Pt 2), 150379
Citation
Zhao, Yonghui; Zuo, Zheng; Qin, Chenhu; Chen, Zongyun; Cao, Zhijian; Wu, Yingliang. (2026). Peptide‑potassium channel interaction law-guided design of Kv1.3 channel-selective peptide immunosuppressants.. International journal of biological macromolecules, 341(Pt 2), 150379. https://doi.org/10.1016/j.ijbiomac.2026.150379